Sarepta Therapeutics, Inc. (SRPT)
| Market Cap | 1.78B |
| Revenue (ttm) | 2.48B |
| Net Income (ttm) | -57.96M |
| Shares Out | 98.28M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,300,169 |
| Open | 18.05 |
| Previous Close | 18.20 |
| Day's Range | 17.97 - 18.92 |
| 52-Week Range | 10.42 - 138.81 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 44.37 (+144.33%) |
| Earnings Date | Aug 6, 2025 |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for SRPT stock is "Hold." The 12-month stock price target is $44.37, which is an increase of 144.33% from the latest price.
News
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations ...
SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Sarepta Therapeutics: A Strong Opportunity Amidst The Panic
Sarepta Therapeutics is trading at a huge discount to previous enterprise value, with significant upside potential as the situation stabilizes in the near term. ELEVIDYS may be able to regain the non-...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired...
Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately ne...
SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT), triggered by a series of safety concerns and regulatory setb...
Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman
SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The pending securities class action was triggered after news of safety problems with Sarepta's (NASDAQ: SRPT) ELEVIDYS, a medication intended for the t...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired...
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has sold 9,265,312 shares of common sto...
SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More
Coinbase and MicroStrategy stocks rose as Bitcoin price surged. Shares of Sarepta, Nvidia and AMD were falling in early trading Monday.
Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2025...
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after the Nas...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT
NEW YORK , July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during t...
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Pr...
SRPT INVESTORS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investors may have been Affected by Fraud – Contact BFA Law by August 25 about Potentially Recovering Losses
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Opinion | On Sarepta, a Welcome FDA Reversal
After our editorial, the agency relents to allow a Duchenne treatment.
Sarepta finally gets some good news: A patient death wasn't its DMD drug's fault.
Sarepta Therapeutics' stock was soaring Tuesday after the FDA recommended lifting the pause on the company's Duchenne muscular dystrophy drug, but analysts worry it will take time for patients and doc...
SRPT Rallies on FDA Green Light: A New Bottom for the Stock?
Sarepta Therapeutics (SRPT) jumped on Tuesday's session after the FDA lifted a voluntary pause on the company's gene therapy treatment for patients with Duchenne muscular dystrophy. The drug was pulle...
FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers
As gene therapies continue to evolve as a promising frontier in medical treatment, regulatory scrutiny intensifies following safety concerns. Recent developments with Sarepta Therapeutics Inc SRPT hig...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you su...
Sarepta: SRPT Stock To $40?
Sarepta Therapeutics is trading around $19 in extended hours following the FDA's decision to remove the pause on Elevidys, marking a critical turning point for the beleaguered biotech. This regulatory...
Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments
Sarepta Therapeutics shares jumped over 36% in premarket trading on Tuesday after the company said it had received US Food and Drug Administration (FDA) approval to restart shipments of its flagship g...